DUBLIN--(BUSINESS WIRE)--The "Antibody Drug Conjugates Market by Drugs - Global Opportunity Analysis and Industry Forecast 2017-2023." report has been added to ResearchAndMarkets.com's offering.
The antibody drug conjugates market was valued at $1,387 million in 2016, and is estimated to reach $3,198 million by 2023, registering a CAGR of 12.9% from 2017 to 2023.
Increase in global prevalence of cancer and demand for quality & cost-effective cancer medications drives the global ADCs market. In addition, extensive R&D for cancer medication and approval of new cancer drugs is expected to boost the market growth during the forecast period. However, high cost involved in R&D of cancer medication and stringent government regulations impedes the growth of antibody drug conjugates market.
The report segments the market based on drugs, mechanism of action, application, and region. Based on drugs, the market is bifurcated into Adcetris and Kadcyla. Based on mechanism of action, it is divided into CD30 antibodies and HER2 antibodies. Based on application, the market is classified into breast cancer, lymphoma, and others.
- F. Hoffman-La Roche Ltd.
- Novartis AG
- Takeda Pharmaceutical Company Limited
- Pfizer, Inc.
- Seattle Genetics Inc.
- Genentech Inc.
- Immunogen Inc.
- Immunomedics, Inc.
- Progenics Pharmaceuticals Inc.
- Bayer AG
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Executive Summary
Chapter 3 Market Overview
Chapter 4 Global Antibody Drug Conjugates Market, By Drugs
Chapter 5 Global Antibody Drug Conjugates Market, By Mechanism Of Action
Chapter 6 Global Antibody Drug Conjugates Market, By Application
Chapter 7 Global Antibody Drug Conjugates Market, By Geography
Chapter 8 Company Profiles
For more information about this report visit https://www.researchandmarkets.com/research/9hfn5k/global_antibody?w=4